Nascent Biotech Overview
- Status
-
Public
- Stock Symbol
-
NBIO
- Investments
-
1
Nascent Biotech General Information
Description
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Contact Information
Website
www.nascentbiotech.comCorporate Office
- 6330 Nancy Ridge Drive
- Suite 105
- San Diego, CA 92121
- United States
Corporate Office
- 6330 Nancy Ridge Drive
- Suite 105
- San Diego, CA 92121
- United States
Nascent Biotech Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 60.7K |
Nascent Biotech Financials Summary
As of 30-Jun-2024, Nascent Biotech has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 14,590 | 30,816 | 6,914 | 6,304 |
| Revenue | 0 | 0 | 0 | 1,000 |
| EBITDA | (1,781) | (1,708) | (1,078) | (134) |
| Net Income | (1,925) | (2,088) | (2,801) | (470) |
| Total Assets | 227 | 552 | 255 | 105 |
| Total Debt | 59 | 122 | 390 | 0 |
Nascent Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nascent Biotech Comparisons
Industry
Financing
Details
Nascent Biotech Competitors (115)
One of Nascent Biotech’s 115 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Protalix Biotherapeutics | Formerly VC-backed | Karmiel, Israel | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Nexoplex bio | Formerly VC-backed | Emeryville, CA | ||||
| Bridge Medicines | Venture Capital-Backed | New York, NY |
Nascent Biotech Patents
Nascent Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021471595-A1 | Kits and containers for treating vimentin expressing tumors | Inactive | 29-Oct-2021 | ||
| CA-3236114-A1 | Kits and containers for treating vimentin expressing tumors | Pending | 29-Oct-2021 | ||
| EP-4422683-A1 | Kits and containers for treating vimentin expressing tumors | Inactive | 29-Oct-2021 | ||
| EP-4422683-A4 | Kits and containers for treating vimentin expressing tumors | Inactive | 29-Oct-2021 | ||
| US-11492394-B1 | Kits and containers for treating vimentin expressing tumors | Active | 29-Oct-2021 | A61P35/00 |
Nascent Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nascent Biotech Acquisitions (1)
Nascent Biotech’s most recent deal was a Merger/Acquisition with Jin-En International Group Holding. The deal was made on 29-Jul-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Jin-En International Group Holding | 29-Jul-2014 | Merger/Acquisition | Biotechnology |
Nascent Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Nascent Biotech FAQs
-
Where is Nascent Biotech headquartered?
Nascent Biotech is headquartered in San Diego, CA.
-
What industry is Nascent Biotech in?
Nascent Biotech’s primary industry is Drug Discovery.
-
Is Nascent Biotech a private or public company?
Nascent Biotech is a Public company.
-
What is Nascent Biotech’s stock symbol?
The ticker symbol for Nascent Biotech is NBIO.
-
Who are Nascent Biotech’s competitors?
Astellas Pharma, Protalix Biotherapeutics, Renova Therapeutics, Nexoplex bio, and Bridge Medicines are some of the 115 competitors of Nascent Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process